Lykke Hinsch Gylvin, Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, posted on LinkedIn:
“We work in disease areas with high unmet needs-where every delay means patients and families keep waiting. That urgency drives how we design our clinical trials. That’s why early, continuous co‑creation with patients and trial sites isn’t optional for us-it’s essential.
100% of our clinical trial designs are co‑created with patients and site staff. Something we are really proud of because it makes a real difference for patients:
- Faster path to registration of new medicines.
Trials designed for real life recruit faster, run more smoothly, and reach readouts sooner. - Outcomes that truly matter
Patients help define endpoints that reflects their lived experience, including how they feel, function, and live with their disease-not just clinical measures. - More patient‑friendly trials.
Visit schedules, procedures, and logistics are shaped around daily life-reducing burden for patients and sites. - More inclusive participation.
Co‑creation helps remove barriers, supporting more representative trial populations.
As one of our patient partners and two‑time cancer survivor Loriana Hernández-Aldama says:
‘building the table together with our voice in it can save lives and change outcomes in ways you could never imagine.’
So yes, that 100% of our trials are co-created with patients makes a real difference: It’s how we move faster, act smarter, and create better treatments-for the patients who can’t afford to wait.”
Other articles featuring Lykke Hinsch Gylvin on OncoDaily.